ACCOUNTS - Final Accounts preparation

Other operating income

As restated

Registered number: 08687703

PRECISIONLIFE LTD

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2025

PRECISIONLIFE LTD

CHAIRMAN'S STATEMENT

FOR THE YEAR ENDED 31 DECEMBER 2025

The chairman presents his statement for the period.

Throughout 2025, PrecisionLife made significant strides and gained considerable momentum. We continued to pursue our aim of providing precision and preventative medicine solutions for complex, chronic conditions with substantial unmet clinical needs.

Our pioneering achievements and papers in ME/CFS, long COVID, endometriosis, ALS, the successful completion of our initial clinical trial involving 400 patients, fresh partnerships in the United States and the Middle East, along with progress on our grant-funded initiatives, have all received widespread recognition. We signed new deals in the US with Kaiser Permanente, in Qatar with the senior national genomics leader, and enrolled patients into our second US clinical study with UMMH.

We helped organize an international symposium for leading experts at Windsor Castle, drawing heavily upon the opportunities unlocked by our discoveries in ME/CFS and long COVID. These breakthroughs have revolutionized the way the wider community understands, diagnoses, and treats these conditions. Currently, we’re engaging with five research teams across the US, UK, Australia, and Europe to initiate innovative drug repurposing trials.

Through our clinical collaborations, we’re converting our innovative discoveries into chances to develop new diagnostic products and targeted drug repurposing trials for conditions currently lacking treatments. These efforts have laid the foundation for a novel category of “Mechanostics®”, which are non-invasive tests offering broad clinical utility from a highly scalable platform. As we advance a new suite of consumer-oriented tests, we are confident that the company stands ready for substantial expansion within the healthcare sector in 2026.

In addition, we are in discussions with senior leadership of US healthcare providers and payors to establish projects and partnerships that will demonstrate the clinical and commercial value of new tests, including triage tests for autoimmune rheumatic diseases with UMMH, and tests to predict the safety, efficacy and tolerability of GLP-1 RA drugs with Ovation and a regional US payor.

Even in a challenging market environment, we have maintained our positive and open culture, with motivated and productive staff members and a highly collaborative work ethic across the teams.

Given the promising commercial prospects ahead and the achievement of all key milestones on our €2.5 million EU EIC grant-enabling the launch of innovative long COVID, endometriosis and chronic pelvic pain triage tests, as well as repurposed treatments-we’re in an excellent position to attract new growth investment.

NameMr Raymond Pawlicki
Chairman

Date8 May 2026

Page 1

PRECISIONLIFE LTD

REGISTERED NUMBER: 08687703

CONSOLIDATED BALANCE SHEET

AS AT 31 DECEMBER 2025

		2025		2024
Note		£		£

Fixed assets
Intangible assets	5		1,102,604		1,175,104
Tangible assets	6		6,683		11,998
			1,109,287		1,187,102
Current assets
Debtors: amounts falling due within one year	8	486,367		792,970
Cash at bank and in hand	9	946,116		433,902
		1,432,483		1,226,872
Creditors: amounts falling due within one year	10	(6,810,892)		(6,019,485)
Net current liabilities			(5,378,409)		(4,792,613)
Total assets less current liabilities			(4,269,122)		(3,605,511)
Net liabilities			(4,269,122)		(3,605,511)

Capital and reserves
Called up share capital	13	163,237	146,273
Share premium account	14	9,859,768	7,230,478
Capital redemption reserve	14	15,275	15,275
Other reserves	14	1,019,307	999,830
Profit and loss account	14	(15,326,709)	(11,997,367)
Equity attributable to owners of the parent Company		(4,269,122)	(3,605,511)
		(4,269,122)	(3,605,511)

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the consolidated statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

Dr S P Gardner

Director

Date: 8 May 2026

The notes on pages 8 to 22 form part of these financial statements.

Page 2

PRECISIONLIFE LTD

REGISTERED NUMBER: 08687703

COMPANY BALANCE SHEET

AS AT 31 DECEMBER 2025

		2025		2024
Note		£		£

Fixed assets
Intangible assets	5		1,102,604		1,175,104
Tangible assets	6		5,775		10,489
Investments	7		7,097		7,097
			1,115,476		1,192,690
Current assets
Debtors: amounts falling due within one year	8	369,543		683,172
Cash at bank and in hand	9	923,807		377,768
		1,293,350		1,060,940
Creditors: amounts falling due within one year	10	(7,296,662)		(6,348,728)
Net current liabilities			(6,003,312)		(5,287,788)
Total assets less current liabilities			(4,887,836)		(4,095,098)


Net liabilities			(4,887,836)		(4,095,098)

Capital and reserves
Called up share capital	13	163,237	146,273
Share premium account	14	9,859,768	7,230,478
Capital redemption reserve	14	15,275	15,275
Other reserves	14	1,019,307	999,830
Profit and loss account	14	(15,945,423)	(12,486,954)
		(4,887,836)	(4,095,098)

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the consolidated statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

Dr S P Gardner

Director

Date: 8 May 2026

The notes on pages 8 to 22 form part of these financial statements.

Page 3


		PRECISIONLIFE LTD

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2025

	Called up share capital	Share premium account	Capital redemption reserve	Share based payment reserve	Profit and loss account	Equity attributable to owners of Parent Company	Total equity
	£	£	£	£	£	£	£
At 1 January 2025	146,273	7,230,478	15,275	999,830	(11,997,367)	(3,605,511)	(3,605,511)
Comprehensive income for the year
Loss for the year	-	-	-	-	(3,326,562)	(3,326,562)	(3,326,562)
Currency translation differences	-	-	-	-	(2,780)	(2,780)	(2,780)
Total comprehensive income for the year	-	-	-	-	(3,329,342)	(3,329,342)	(3,329,342)
Contributions by and distributions to owners
Shares issued during the year	16,964	2,629,290	-	-	-	2,646,254	2,646,254
Share based payment	-	-	-	19,477	-	19,477	19,477
Total transactions with owners	16,964	2,629,290	-	19,477	-	2,665,731	2,665,731
At 31 December 2025	163,237	9,859,768	15,275	1,019,307	(15,326,709)	(4,269,122)	(4,269,122)

The notes on pages 8 to 22 form part of these financial statements.

Page 4


		PRECISIONLIFE LTD

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2024

	Called up share capital	Share premium account	Capital redemption reserve	Share based payment reserve	Profit and loss account	Total equity
	£	£	£	£	£	£
At 1 January 2024	139,977	6,254,576	15,275	792,558	(8,183,747)	(981,361)
Comprehensive income for the year
Loss for the year	-	-	-	-	(3,822,807)	(3,822,807)
Currency translation differences	-	-	-	-	(20,431)	(20,431)
Total comprehensive income for the year	-	-	-	-	(3,843,238)	(3,843,238)
Contributions by and distributions to owners
Shares issued during the year	6,296	975,902	-	-	-	982,198
Transfer to/from profit and loss account	-	-	-	(29,618)	29,618	-
Share based payments	-	-	-	236,890	-	236,890
Total transactions with owners	6,296	975,902	-	207,272	29,618	1,219,088
At 31 December 2024	146,273	7,230,478	15,275	999,830	(11,997,367)	(3,605,511)

The notes on pages 8 to 22 form part of these financial statements.

Page 5


		PRECISIONLIFE LTD

COMPANY STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2025

	Called up share capital	Share premium account	Capital redemption reserve	Share based payment reserve	Profit and loss account	Total equity
	£	£	£	£	£	£
At 1 January 2025	146,273	7,230,478	15,275	999,830	(12,486,954)	(4,095,098)
Comprehensive income for the year
Loss for the year	-	-	-	-	(3,458,469)	(3,458,469)
Total comprehensive income for the year	-	-	-	-	(3,458,469)	(3,458,469)
Contributions by and distributions to owners
Shares issued during the year	16,964	2,629,290	-	-	-	2,646,254
Share based payments	-	-	-	19,477	-	19,477
Total transactions with owners	16,964	2,629,290	-	19,477	-	2,665,731
At 31 December 2025	163,237	9,859,768	15,275	1,019,307	(15,945,423)	(4,887,836)

The notes on pages 8 to 22 form part of these financial statements.

Page 6


		PRECISIONLIFE LTD

COMPANY STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2024

	Called up share capital	Share premium account	Capital redemption reserve	Share based payment reserve	Profit and loss account	Total equity
	£	£	£	£	£	£
At 1 January 2024	139,977	6,254,576	15,275	792,558	(8,634,398)	(1,432,012)
Comprehensive income for the period
Loss for the period	-	-	-	-	(3,882,174)	(3,882,174)
Total comprehensive income for the period	-	-	-	-	(3,882,174)	(3,882,174)
Contributions by and distributions to owners
Shares issued during the year	6,296	975,902	-	-	-	982,198
Transfer to/from profit and loss account	-	-	-	(29,618)	29,618	-
Shares issued	-	-	-	236,890	-	236,890
Total transactions with owners	6,296	975,902	-	207,272	29,618	1,219,088
At 31 December 2024	146,273	7,230,478	15,275	999,830	(12,486,954)	(4,095,098)

The notes on pages 8 to 22 form part of these financial statements.

Page 7

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

1.	General information

Precisionlife Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Unit 8b Bankside, Hanborough Business Park, Long Hanborough, Witney, Oxon, OX29 8LJ.

The principal activity of the company in the period under review was that of the analysis of large-scale patient datasets for healthcare and biotech/pharma precision medicine applications, identifying new therapeutic options for patients with unmet medical needs.

2.Accounting policies

2.1

Basis of preparation of financial statements

The consolidated financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the requirements and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of comprehensive income in these financial statements.

The financial statements have been rounded to the nearest pound Sterling.

The following principal accounting policies have been applied:

2.2

Basis of consolidation

The consolidated financial statements present the results of the Company and its own subsidiaries ("the Group") as if they form a single entity. Intercompany transactions and balances between group companies are therefore eliminated in full.

The consolidated financial statements incorporate the results of business combinations using the purchase method. In the Balance sheet, the acquiree's identifiable assets, liabilities and contingent liabilities are initially recognised at their fair values at the acquisition date. The results of acquired operations are included in the Consolidated statement of comprehensive income from the date on which control is obtained. They are deconsolidated from the date control ceases.

2.3

Going concern

While the directors believe that the assumptions made in arriving at the company’s base case cashflows are appropriate, there is inherent uncertainty in the future ability to obtain further funding from existing shareholders or other third-party sources. While the directors are confident that funding will be obtained, such agreement has not yet been obtained and may be subject to conditions and milestones by the provider of such funding. Therefore, a degree of material uncertainty exists that may cast doubt on the company’s ability to continue as a going concern and to realise its assets and discharge its liabilities in the normal course of business. The directors consider this an unlikely scenario, particularly in light of current progress on attracting new investment, good progress on grant funded projects, interest from senior leadership of major healthcare payors and providers as well as global diagnostics businesses and the company’s revenue potential from launch of new diagnostic products.

Notwithstanding this material uncertainty, having assessed likely downside scenarios and the mitigations available and being confident that refinancing will be achieved, the directors have formed the judgement that it is appropriate to prepare the financial statements on a going concern basis.

Page 8

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

2.4

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Consolidated statement of comprehensive income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

On consolidation, the results of overseas operations are translated into Sterling at rates approximating to those ruling when the transactions took place. All assets and liabilities of overseas operations are translated at the rate ruling at the reporting date. Exchange differences arising on translating the opening net assets at opening rate and the results of overseas operations at actual rate are recognised in other comprehensive income.

2.5

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

∙the amount of revenue can be measured reliably;

∙it is probable that the Group will receive the consideration due under the contract;

∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and

∙the costs incurred and the costs to complete the contract can be measured reliably.

Page 9

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

2.6

Operating leases: the Group as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

2.7

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

2.8

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.

Grants of a revenue nature are recognised in the Consolidated statement of comprehensive income in the same period as the related expenditure.

2.9

Interest income

Interest income is recognised in profit or loss using the effective interest method.

2.10

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

2.11

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

2.12

Pensions

Defined contribution pension plan

The Group operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Group pays fixed contributions into a separate entity. Once the contributions have been paid the Group has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Group in independently administered funds.

Page 10

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

2.13

Share-based payments

Where share options are awarded to employees, the fair value of the options at the date of grant is charged to profit or loss over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each balance sheet date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options granted. The cumulative expense is not adjusted for failure to achieve a market vesting condition.

The fair value of the award also takes into account non-vesting conditions. These are either factors beyond the control of either party (such as a target based on an index) or factors which are within the control of one or other of the parties (such as the Group keeping the scheme open or the employee maintaining any contributions required by the scheme).

Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to profit or loss over the remaining vesting period.

Where equity instruments are granted to persons other than employees, profit or loss is charged with fair value of goods and services received.

2.14

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company and the Group operate and generate income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:

∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits;

∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met; and

∙Where they relate to timing differences in respect of interests in subsidiaries, associates, branches and joint ventures and the Group can control the reversal of the timing differences and such reversal is not considered probable in the foreseeable future.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Page 11

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

2.15

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

2.16

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and machinery	-	25%	straight line basis
Fixtures and fittings	-	25%	straight line basis
Computer equipment	-	33%	straight line basis

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

2.17

Impairment of fixed assets and goodwill

Assets that are subject to depreciation or amortisation are assessed at each balance sheet date to determine whether there is any indication that the assets are impaired. Where there is any indication that an asset may be impaired, the carrying value of the asset (or cash-generating unit to which the asset has been allocated) is tested for impairment. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's (or CGU's) fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (CGUs). Non-financial assets that have been previously impaired are reviewed at each balance sheet date to assess whether there is any indication that the impairment losses recognised in prior periods may no longer exist or may have decreased.

2.18

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Other investments are carried at fair value with gains and losses reflected in the profit and loss account.

Page 12

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

2.19

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.20

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.21

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.22

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.

Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.

Increases in provisions are generally charged as an expense to profit or loss.

2.23

Convertible debt

The proceeds received on issue of the Group's convertible debt are allocated into their liability and equity components and presented separately in the Balance sheet.

The amount initially attributed to the debt component equals the discounted cash flows using a market rate of interest that would be payable on a similar debt instrument that did not include an option to convert.

The difference between the net proceeds of the convertible debt and the amount allocated to the debt component is credited direct to equity and is not subsequently remeasured. On conversion, the debt and equity elements are credited to share capital and share premium as appropriate.

Transaction costs that relate to the issue of the instrument are allocated to the liability and equity components of the instrument in proportion to the allocation of proceeds.

Page 13

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

Government grants receivable	718,763	247,236
RDEC	233,338	72,499
	952,101	319,735

Page 14

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

Employees

The average monthly number of employees, including the directors, during the year was as follows:

	Group	Group	Company	Company
	2025	2024	2025	2024
	No.	No.	No.	No.

Employees	34	38	23	25

5.	Intangible assets
	Group and Company

		Intellectual Property Rights
		£
	Cost
	At 1 January 2025	1,450,000
	At 31 December 2025	1,450,000
	Amortisation
	At 1 January 2025	274,896
	Charge for the year on owned assets	72,500
	At 31 December 2025	347,396
	Net book value
	At 31 December 2025	1,102,604
	At 31 December 2024	1,175,104

Page 15

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

6.	Tangible fixed assets
	Group

	Plant and machinery	Fixtures and fittings	Computer equipment	Total
	£	£	£	£
Cost or valuation
At 1 January 2025	10,073	16,761	92,664	119,498
At 31 December 2025	10,073	16,761	92,664	119,498
Depreciation
At 1 January 2025	8,564	16,761	82,175	107,500
Charge for the year on owned assets	601	-	4,714	5,315
At 31 December 2025	9,165	16,761	86,889	112,815
Net book value
At 31 December 2025	908	-	5,775	6,683
At 31 December 2024	1,509	-	10,489	11,998

Page 16

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

6.Tangible fixed assets (continued)

	Company

	Fixtures and fittings	Computer equipment	Total
	£	£	£
Cost or valuation
At 1 January 2025	16,761	88,648	105,409
At 31 December 2025	16,761	88,648	105,409
Depreciation
At 1 January 2025	16,761	78,159	94,920
Charge for the year on owned assets	-	4,714	4,714
At 31 December 2025	16,761	82,873	99,634
Net book value
At 31 December 2025	-	5,775	5,775
At 31 December 2024	-	10,489	10,489

Page 17

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

7.	Fixed asset investments

	Company

		Investments in subsidiaries
		£
	Cost or valuation
	At 1 January 2025	7,097
	At 31 December 2025	7,097

The subsidiaries are Rowanalytics SP Zoo, Rowanalytics APS and Rowanalytics Inc which are incorporated in Poland, Denmark and USA respectively. The company owns 100% of these companies.

Page 18

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

Debtors

Group	Group	Company	Company
2025	2024	2025	2024
£	£	£	£


Trade debtors	21,358	146,925	21,359	146,925
Other debtors	89,765	81,428	25,751	24,098
Prepayments and accrued income	172,484	212,743	122,418	161,797
Tax recoverable	202,642	351,803	200,015	350,352
Deferred taxation	118	71	-	-
	486,367	792,970	369,543	683,172

9.	Cash and cash equivalents
		Group	Group	Company	Company
		2025	2024	2025	2024
		£	£	£	£

Cash at bank and in hand	946,116	433,902	923,807	377,768
	946,116	433,902	923,807	377,768

10.	Creditors: Amounts falling due within one year
		Group	Group	Company	Company
		2025	2024	2025	2024
		£	£	£	£

Other loans	4,619,818	4,058,756	4,619,818	4,058,756
Trade creditors	212,559	166,394	189,984	158,736
Amounts owed to group undertakings	-	-	571,383	389,852
Corporation tax	4,305	4,299	-	-
Other taxation and social security	84,474	107,889	56,003	85,177
Other creditors	788,225	849,574	762,892	828,265
Accruals and deferred income	1,101,511	832,573	1,096,582	827,942
	6,810,892	6,019,485	7,296,662	6,348,728

Page 19

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025


11.	Convertible loan notes

Convertible loan notes accrue interest at a rate of 7% per annum and are convertible at any time up until the settlement dates at the option of the note holder. Proceeds from the issue of convertible loans have been wholly recognised as a liability.

12.	Loans
	Analysis of the maturity of loans is given below:
		Group	Group	Company	Company
		2025	2024	2025	2024
		£	£	£	£

Amounts falling due within one year
Other loans	4,619,818	4,058,756	4,619,818	4,058,756
	4,619,818	4,058,756	4,619,818	4,058,756



	4,619,818	4,058,756	4,619,818	4,058,756

13.	Share capital
		2025	2024
		£	£

Allotted, called up and fully paid

9,347,222 (2024 - 9,347,200) Ordinary shares of £0.01 each	93,472	93,472
5,066,954 (2024 - 3,370,600) Class A1 shares of £0.01 each	50,670	33,706
1,909,500 (2024 - 1,909,500) Class A2 shares of £0.01 each	19,095	19,095

	163,237	146,273

1,696,318 Ordinary A1 shares with nominal value of £0.01 each were issued in the year for a total consideration of £2,646,253

Page 20

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

14.

Reserves

Share premium account

This reserve records the amount above the nominal value received for shares sold, less transaction costs.

Profit and loss account

The profit and loss account is the Group's accumulated profits or losses at the year end date.

Share based payment reserve

The share based payment reserve is the Company's accumulated charge in respect of share based payments recognised in the profit and loss.

15.	Pension commitments

The Group operates a defined contributions pension scheme. The pension cost charge represents contributions payable by the Group to the fund and amounted to £55,557 (2024: £81,397). Contributions totalling £22,541 (2024: £24,468) were payable at the balance sheet date.

16.	Commitments under operating leases
	At 31 December 2025 the Group and the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:
		Group	Group	Company	Company
		2025	2024	2025	2024
		£	£	£	£

Not later than 1 year	38,805	26,119	38,805	26,119
Later than 1 year and not later than 5 years	155,220	-	155,220	-
Later than 5 years	29,104	-	29,104	-
	223,129	26,119	223,129	26,119

17.	Related party transactions
	Transactions with wholly owned subsidiaries are not disclosed as related party transactions, as permitted by FRS 102.

18.	Post balance sheet events

On 30 March 2026 851,535 A1 ordinary shares, with a nominal value of £0.001 each were issued for a total consideration of $1,752,819.

19.	Controlling party

In the opinion of the directors, there is not one controlling party

Page 21

PRECISIONLIFE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

20.	Auditor's information

The auditor's report on the financial statements for the year ended 31 December 2025 was unqualified.

In their report, the auditor emphasised the following matter without qualifying their report:

Material uncertainty related to going concern

In forming our opinion on the financial statements, which is not qualified, we have considered the adequacy of the disclosure in note 2.3 to the financial statements concerning the directors' use of the going concern basis of accounting in the preparation of the financial statements.

The financial statements have been prepared on a going concern basis, the validity of which depends upon the success of the directors in raising additional funds from investors and/or from trading activities as described in note 2.3, which are inherently uncertain. The uncertainty over these activities indicates the existence of a material uncertainty which may cast doubt on the Group's ability to continue as a going concern. The financial statements do not include adjustments that would be necessary if the Group was unable to continue as a going concern.

In auditing the financial statements, we have concluded that the Directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

The audit report was signed on 8 May 2026 by Alan Poole BA (Hons) FCA (Senior statutory auditor) on behalf of James Cowper Kreston Audit.

Page 22